Pharmaceuticals News and Research

RSS

NIH award reflects urgency of overcoming infections that resist drug treatment

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health has selected infectious disease expert David Perlin, executive director of the Public Health Research Institute at Rutgers New Jersey Medical School, to lead a major research effort aimed at developing new forms of antibiotics to regain the upper hand over deadly bacteria that have become resistant to current treatments.

26 Apr 2014

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Concert Pharmaceuticals, Inc. today announced 48-week results of its Phase 2 clinical trial of CTP-499 in patients with diabetic kidney disease. CTP-499, when used in addition to the standard of care, is being developed to delay the progression of these patients to end-stage renal failure, which requires dialysis or kidney transplantation.

26 Apr 2014

Lilly launches second medical student education program

Eli Lilly and Company announced today the launch of another medical student education program, an internship for aspiring physicians.

26 Apr 2014

Pernix completes sale of Pernix Manufacturing to Woodfield Pharmaceutical

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced that it has closed on the sale of its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC ("PML") to Woodfield Pharmaceutical LLC.

25 Apr 2014

Swander Pace Capital sells Insight Pharmaceuticals to Prestige Brands Holdings for $750 million

Swander Pace Capital, a leading private equity firm specializing in investments in consumer products companies, announced today that it is selling its over-the-counter (OTC) products portfolio company, Insight Pharmaceuticals, to Prestige Brands Holdings for $750 million.

25 Apr 2014

Alimera Sciences inks Loan and Security Agreement with Hercules Technology Growth Capital

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that its United Kingdom subsidiary, Alimera Sciences Limited, has entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. for a term loan in the principal amount of up to $35 million.

25 Apr 2014

Prestige Brands Holdings signs agreement to acquire Insight Pharmaceuticals for $750 million

Prestige Brands Holdings, Inc. today announced that it has entered into a definitive agreement to acquire Insight Pharmaceuticals Corporation, a marketer and distributor of feminine care and other over-the-counter ("OTC") healthcare products, for $750 million in cash.

25 Apr 2014

NIAMS scientific director to receive 2014 Ross Prize in Molecular Medicine

John J. O'Shea, M.D., scientific director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), has been named the 2014 recipient of the Ross Prize in Molecular Medicine, conferred by the Feinstein Institute's peer-reviewed, open-access journal Molecular Medicine.

25 Apr 2014

NPF researchers to get access to Corrona’s psoriatic arthritis registry to improve patient outcomes

To improve treatment decisions and patient outcomes for psoriatic arthritis (PsA)—a chronic inflammatory arthritis that affects the joints and tendons—the National Psoriasis Foundation and Corrona, LLC are collaborating to give NPF-affiliated researchers access to Corrona’s psoriatic arthritis registry, which is the largest psoriatic arthritis registry in the world.

25 Apr 2014

Viewpoints: Health spending ready to start climbing again; Cruz's 'nightmare' comes true

Standing before a roomful of economists, policy makers and health care experts earlier this month, Amitabh Chandra, director of Health Policy Research at Harvard's Kennedy School of Government, closed a presentation about the slowdown in health care spending over the last decade by citing an article in The New York Times.

25 Apr 2014

Tolero Pharmaceuticals' Alvocidib gets Orphan Drug Designation for acute myeloid leukemia treatment

Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the U.S. Food and Drug Administration has granted Orphan Drug designation for Alvocidib for the treatment of patients with acute myeloid leukemia (AML).

23 Apr 2014

NeoGenomics' revenue up 16.1% in first quarter 2014

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2014.

23 Apr 2014

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its pivotal trial of Captisol-enabled (propylene glycol-free) Melphalan met its primary end points.

23 Apr 2014

NovaBay introduces new eye care product to help patients with eyelids irritation

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it is introducing a new eye care product, i-Lid Cleanser.

23 Apr 2014

Nuvo Research collaborates with Ferndale to develop 2 topical dermatology products

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced a collaboration involving Ferndale Laboratories, Inc. and a leading Contract Research Organization with significant dermatology experience to develop two topical dermatology products based on Nuvo's patented Multiplexed Molecular Penetration Enhancer technology.

23 Apr 2014

HemoShear announces research collaboration with Medivir

HemoShear, LLC, the human disease biology company, today announced research collaboration with Medivir AB of Stockholm, Sweden, an emerging research-based pharmaceutical company focused on infectious diseases.

23 Apr 2014

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.

23 Apr 2014

Kala Pharmaceuticals completes $22.5 million Series B financing

Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company's proprietary Mucus Penetrating Particle (MPP) platform technology, today announced it has completed a $22.5 million Series B financing.

23 Apr 2014

TWi and Endo Pharmaceuticals settle patent litigation over Lidoderm product

TWi Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. to settle all outstanding patent litigation related to TWi's lidocaine topical patch 5% product.

23 Apr 2014

Exposure to microgravity can simulate aging for immune cells

Telling someone to "act your age" is another way of asking him or her to behave better. Age, however, does not always bring improvements.

23 Apr 2014

Pharmaceuticals News and Research

NIH award reflects urgency of overcoming infections that resist drug treatment

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Lilly launches second medical student education program

Pernix completes sale of Pernix Manufacturing to Woodfield Pharmaceutical

Swander Pace Capital sells Insight Pharmaceuticals to Prestige Brands Holdings for $750 million

Alimera Sciences inks Loan and Security Agreement with Hercules Technology Growth Capital

Prestige Brands Holdings signs agreement to acquire Insight Pharmaceuticals for $750 million

NIAMS scientific director to receive 2014 Ross Prize in Molecular Medicine

NPF researchers to get access to Corrona’s psoriatic arthritis registry to improve patient outcomes

Viewpoints: Health spending ready to start climbing again; Cruz's 'nightmare' comes true

Tolero Pharmaceuticals' Alvocidib gets Orphan Drug Designation for acute myeloid leukemia treatment

NeoGenomics' revenue up 16.1% in first quarter 2014

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

NovaBay introduces new eye care product to help patients with eyelids irritation

Nuvo Research collaborates with Ferndale to develop 2 topical dermatology products

HemoShear announces research collaboration with Medivir

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Kala Pharmaceuticals completes $22.5 million Series B financing

TWi and Endo Pharmaceuticals settle patent litigation over Lidoderm product

Exposure to microgravity can simulate aging for immune cells

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence